WO2008109454A8 - Nucleic acid compounds for inhibiting fos gene expression and uses thereof - Google Patents

Nucleic acid compounds for inhibiting fos gene expression and uses thereof Download PDF

Info

Publication number
WO2008109454A8
WO2008109454A8 PCT/US2008/055524 US2008055524W WO2008109454A8 WO 2008109454 A8 WO2008109454 A8 WO 2008109454A8 US 2008055524 W US2008055524 W US 2008055524W WO 2008109454 A8 WO2008109454 A8 WO 2008109454A8
Authority
WO
Grant status
Application
Patent type
Prior art keywords
fos
nucleic acid
gene expression
fos gene
inhibiting
Prior art date
Application number
PCT/US2008/055524
Other languages
French (fr)
Other versions
WO2008109454A4 (en )
WO2008109454A2 (en )
WO2008109454A3 (en )
Inventor
Mohammad Ahmadian
James Mcswiggen
Steven C Quay
Narendra K Vaish
Original Assignee
Mohammad Ahmadian
James Mcswiggen
Mdrna Inc
Steven C Quay
Narendra K Vaish
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/111Antisense spanning the whole gene, or a large part of it
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed

Abstract

The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing FOS gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a FOS mRNA. In addition, the meroduplex may have at least one uridine is a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a FOS gene in a cell or in a subject to treat a FOS-related disease.
PCT/US2008/055524 2007-03-02 2008-02-29 Nucleic acid compounds for inhibiting fos gene expression and uses thereof WO2008109454A8 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US93494007 true 2007-03-02 2007-03-02
US60/934,940 2007-03-02
US93493007 true 2007-03-16 2007-03-16
US60/934,930 2007-03-16
US1473007 true 2007-12-18 2007-12-18
US61/014,730 2007-12-18

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12552082 US20100105134A1 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof
US13327545 US20130011922A1 (en) 2007-03-02 2011-12-15 Nucleic acid compounds for inhibiting gene expression and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055572 Continuation-In-Part WO2008106664A3 (en) 2007-03-01 2008-02-29 Human behavioral modeling and simulation framework

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2008/055635 Continuation-In-Part WO2008109511B1 (en) 2007-03-02 2008-03-03 Nucleic acid compounds for inhibiting fcer2 gene expression and uses thereof
US12552082 Continuation-In-Part US20100105134A1 (en) 2007-03-01 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof
AU2009212920A Division AU2009212920A8 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof

Publications (4)

Publication Number Publication Date
WO2008109454A2 true WO2008109454A2 (en) 2008-09-12
WO2008109454A3 true WO2008109454A3 (en) 2008-12-11
WO2008109454A4 true WO2008109454A4 (en) 2009-02-12
WO2008109454A8 true true WO2008109454A8 (en) 2009-07-16

Family

ID=39513291

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055524 WO2008109454A8 (en) 2007-03-02 2008-02-29 Nucleic acid compounds for inhibiting fos gene expression and uses thereof

Country Status (1)

Country Link
WO (1) WO2008109454A8 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050079610A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
US20050136437A1 (en) * 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
EP1942943A2 (en) * 2005-11-04 2008-07-16 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna

Also Published As

Publication number Publication date Type
WO2008109454A4 (en) 2009-02-12 application
WO2008109454A2 (en) 2008-09-12 application
WO2008109454A3 (en) 2008-12-11 application

Similar Documents

Publication Publication Date Title
Gomez et al. Telomerase downregulation induced by the G‐quadruplex ligand 12459 in A549 cells is mediated by hTERT RNA alternative splicing
Guo et al. CELL-SELEX: Novel perspectives of aptamer-based therapeutics
WO2002055692A3 (en) Method for inhibiting the expression of a target gene and medicament for treating a tumor disease
WO2006066158A3 (en) Rnai modulation of mll-af4 and uses thereof
WO2009078470A1 (en) Complex of polysaccharide and double-stranded rna
WO2005121371A3 (en) Double strand compositions comprising differentially modified strands for use in gene modulation
WO2004015107A3 (en) Further novel forms of interfering rna molecules
Agarwal et al. Furan based cyclic homo-oligopeptides bind G-quadruplex selectively and repress c-MYC transcription
WO2004007718A3 (en) Rna-interference by single-stranded rna molecules
WO2008073920A3 (en) Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2008091934A3 (en) Fructose 1, 6 bisphosphate - a novel anticonvulsant drug
WO2003074654A3 (en) Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
WO2005105995A3 (en) RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA)
Nishiyama et al. pH-Dependence of the thermal stability of metallo-DNA duplexes containing ligand-type 5-hydroxyuracil nucleobases
Hasler et al. An argonaute protein directs nuclear Xrn2 function
WO2004046160A8 (en) Amino-lna, thio-lna and alpha-l-oxy-ln
Herdewijn et al. Nucleic acids with a six-membered carbohydrate mimic and RNA interference
WO2007020457A3 (en) Labelled modified guanine- containing nucleosides and nucleotides comprising a fluorophore attached to the base through a linking group comprising a polyethylene glycol spacing group and methods for their use
WO2008073919A3 (en) Mir-20 regulated genes and pathways as targets for therapeutic intervention
WO2004065600A3 (en) Rna interference by palindromic or modified rna molecules
WO2007130604A3 (en) Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna
WO2011005860A3 (en) 5' phosphate mimics
WO2003070910A3 (en) INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731148

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 08731148

Country of ref document: EP

Kind code of ref document: A2